China Resources Boya Bio pharmaceutical Group Co Ltd (300294) - Total Liabilities
Based on the latest financial reports, China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has total liabilities worth CN¥1.05 Billion CNY (≈ $154.33 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 300294 operating cash flow to assess how effectively this company generates cash.
China Resources Boya Bio pharmaceutical Group Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of China Resources Boya Bio pharmaceutical to evaluate the company's liquid asset resilience ratio.
China Resources Boya Bio pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of China Resources Boya Bio pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guilin Fuda Co Ltd
SHG:603166
|
China | CN¥2.10 Billion |
|
Nolato AB (publ)
ST:NOLA-B
|
Sweden | Skr3.75 Billion |
|
Shaanxi Provincial Natural Gas Co Ltd
SHE:002267
|
China | CN¥7.07 Billion |
|
Savers Value Village, Inc.
NYSE:SVV
|
USA | $1.58 Billion |
|
Forestar Group Inc
NYSE:FOR
|
USA | $1.39 Billion |
|
Shenzhen Vital New Material Co. Ltd.
SHE:301319
|
China | CN¥299.17 Million |
|
Jiangsu Zhenjiang New Energy Equipment Co Ltd Class A
SHG:603507
|
China | CN¥5.38 Billion |
|
Kernel Holding SA
F:0KE
|
Germany | €1.19 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300294 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Resources Boya Bio pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual total liabilities of China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥913.38 Million ≈ $133.66 Million |
+79.77% |
| 2023-12-31 | CN¥508.07 Million ≈ $74.35 Million |
-32.11% |
| 2022-12-31 | CN¥748.35 Million ≈ $109.51 Million |
+6.71% |
| 2021-12-31 | CN¥701.30 Million ≈ $102.62 Million |
-27.41% |
| 2020-12-31 | CN¥966.08 Million ≈ $141.37 Million |
-23.82% |
| 2019-12-31 | CN¥1.27 Billion ≈ $185.56 Million |
-2.65% |
| 2018-12-31 | CN¥1.30 Billion ≈ $190.61 Million |
+9.89% |
| 2017-12-31 | CN¥1.19 Billion ≈ $173.45 Million |
+312.58% |
| 2016-12-31 | CN¥287.30 Million ≈ $42.04 Million |
+2.57% |
| 2015-12-31 | CN¥280.11 Million ≈ $40.99 Million |
+198.30% |
| 2014-12-31 | CN¥93.90 Million ≈ $13.74 Million |
-40.51% |
| 2013-12-31 | CN¥157.85 Million ≈ $23.10 Million |
+511.75% |
| 2012-12-31 | CN¥25.80 Million ≈ $3.78 Million |
-62.32% |
| 2011-12-31 | CN¥68.48 Million ≈ $10.02 Million |
-29.97% |
| 2010-12-31 | CN¥97.79 Million ≈ $14.31 Million |
-35.64% |
| 2009-12-31 | CN¥151.93 Million ≈ $22.23 Million |
+77.72% |
| 2008-12-31 | CN¥85.49 Million ≈ $12.51 Million |
-- |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. It offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. The company also provides bone peptide, oxytocin, heparin sodium, and posterior pituitary injection produ… Read more